Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Launched by TECHNISCHE UNIVERSITÄT DRESDEN · Jun 13, 2017
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) is a research study focused on understanding acute myeloid leukemia (AML) in adults who have just been diagnosed or are experiencing a relapse of the disease. This study is taking place at 51 locations across Germany and aims to gather important information about the disease, including how common it is, the factors that might influence a patient's outcome, and how long patients can expect to live without the disease coming back after treatment. By collecting this data, researchers hope to improve treatment strategies for AML in the future.
To participate in this study, adults aged 18 and older who have been diagnosed with AML, including a specific type called acute promyelocytic leukemia, can sign up. There are no upper age limits for this trial, and patients will be asked to give their written consent to participate. Once enrolled, participants can expect to have their treatment documented, and their progress tracked over time to better understand the disease and its outcomes. This research is crucial for helping doctors provide better care for those affected by AML.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
- • Age ≥ 18 years. There is no upper age limit.
- • Signed written informed consent
- Exclusion Criteria:
- • there are no exclusion criteria
About Technische Universität Dresden
Technische Universität Dresden (TU Dresden) is a leading research institution in Germany, renowned for its commitment to advancing scientific knowledge and innovation across various disciplines, including medicine and healthcare. As a clinical trial sponsor, TU Dresden leverages its cutting-edge research facilities and interdisciplinary expertise to facilitate the development of novel therapeutic interventions and improve patient outcomes. The university fosters collaboration among academic, clinical, and industry partners, ensuring rigorous adherence to ethical standards and regulatory requirements in the conduct of clinical research. Through its dedication to excellence and research-driven initiatives, TU Dresden plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erlangen, Bayern, Germany
Kiel, Schleswig Holstein, Germany
Leipzig, Sachsen, Germany
Berlin, , Germany
Aachen, Nordrhein Westfalen, Germany
Altenburg, , Germany
Leipzig, Sachsen, Germany
Jena, , Germany
Würzburg, Bayern, Germany
Augsburg, Bayern, Germany
Dresden, Sachsen, Germany
Halle (Saale), Sachsen Anhalt, Germany
Stuttgart, , Germany
Winnenden, , Germany
Düsseldorf, Nordrhein Westfalen, Germany
Frankfurt Am Main, Hessen, Germany
Münster, Nordrhein Westfalen, Germany
Halle (Saale), Sachsen Anhalt, Germany
Stendal, Sachsen Anhalt, Germany
Mannheim, , Germany
Chemnitz, Sachsen, Germany
Baden Baden, Baden Württemberg, Germany
Heidelberg, Baden Württemberg, Germany
Mannheim, Baden Württemberg, Germany
Schwäbisch Hall, Baden Württemberg, Germany
Sindelfingen, Baden Württemberg, Germany
Stuttgart, Baden Württemberg, Germany
Winnenden, Baden Württemberg, Germany
Bamberg, Bayern, Germany
Bayreuth, Bayern, Germany
Coburg, Bayern, Germany
Nürnberg, Bayern, Germany
Cottbus, Brandenburg, Germany
Frankfurt An Der Oder, Brandenburg, Germany
Fulda, Hessen, Germany
Marburg, Hessen, Germany
Wiesbaden, Hessen, Germany
Hildesheim, Niedersachsen, Germany
Rotenburg, Niedersachsen, Germany
Siegen, Nordhein Westfalen, Germany
Düren, Nordrhein Westfalen, Germany
Bielefeld, Nordrhein Westfalen, Germany
Bochum, Nordrhein Westfalen, Germany
Essen, Nordrhein Westfalen, Germany
Gütersloh, Nordrhein Westfalen, Germany
Hamm, Nordrhein Westfalen, Germany
Kaiserslautern, Rheinland Pfalz, Germany
Koblenz, Rheinland Pfalz, Germany
Riesa, Sachsen, Germany
Kiel, Schleswig Holstein, Germany
Altenburg, Thüringen, Germany
Jena, Thüringen, Germany
Bremen, , Germany
Baden Baden, , Germany
Neubrandenburg, Mecklenburg Vorpommern, Germany
Rostock, Mecklenburg Vorpommern, Germany
Duisburg, Nordrhein Westfalen, Germany
Siegen, Nordrhein Westfalen, Germany
Heidelberg, , Germany
Schwäbisch Hall, , Germany
Sindelfingen, , Germany
Patients applied
Trial Officials
Christoph Röllig, Prof. Dr.
Study Director
Universitätsklinikum Carl Gustav Carus
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials